Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer.

cancer immunotherapy first-line treatment immune checkpoint inhibitors (ICIs) non-small cell lung cancers (NSCLC) observational study overall survival (OS) real-world evidence real-world progression-free survival (rwPFS)

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
15 Sep 2022
Historique:
received: 05 08 2022
revised: 09 09 2022
accepted: 13 09 2022
entrez: 23 9 2022
pubmed: 24 9 2022
medline: 24 9 2022
Statut: epublish

Résumé

This study provides insights into the treatment use and outcomes of metastatic non-small cell lung cancer (NSCLC) patients in a real-world setting prior to and after the availability of immuno-oncology (IO) regimens in the first line (1L). Metastatic NSCLC patients, who initiated systemic 1L anticancer treatment from 2014 to 2020, were identified from health records. Patients were grouped into Pre-1L IO and Post-1L IO, according to the availability of pembrolizumab 1L monotherapy at the date of initiating 1L systemic anticancer treatment. Patient characteristics, treatment patterns and outcomes were assessed by the cohort. Overall survival (OS) and real-world progression-free survival (rwPFS) were calculated using the Kaplan-Meier method. The most common 1L treatment was platinum-based chemotherapy regimens in both groups (≥46%), followed by single-agent chemotherapy (27.0%) in Pre-1L IO and pembrolizumab (26.0%) in Post-1L IO. Median OS was 6.2 (95% CI 5.5-7.4) in Pre- and 8.9 months (95% CI 7.5-10.6) in Post-1L IO, while rwPFS was 3.7 (95% CI 3.3-4.2) and 4.7 months (95% CI 3.9-5.7), respectively. Even if a small proportion of patients received a 1L IO, the data showed an improved survival outcomes in the Post-1L IO group.

Sections du résumé

BACKGROUND BACKGROUND
This study provides insights into the treatment use and outcomes of metastatic non-small cell lung cancer (NSCLC) patients in a real-world setting prior to and after the availability of immuno-oncology (IO) regimens in the first line (1L).
METHODS METHODS
Metastatic NSCLC patients, who initiated systemic 1L anticancer treatment from 2014 to 2020, were identified from health records. Patients were grouped into Pre-1L IO and Post-1L IO, according to the availability of pembrolizumab 1L monotherapy at the date of initiating 1L systemic anticancer treatment. Patient characteristics, treatment patterns and outcomes were assessed by the cohort. Overall survival (OS) and real-world progression-free survival (rwPFS) were calculated using the Kaplan-Meier method.
RESULTS RESULTS
The most common 1L treatment was platinum-based chemotherapy regimens in both groups (≥46%), followed by single-agent chemotherapy (27.0%) in Pre-1L IO and pembrolizumab (26.0%) in Post-1L IO. Median OS was 6.2 (95% CI 5.5-7.4) in Pre- and 8.9 months (95% CI 7.5-10.6) in Post-1L IO, while rwPFS was 3.7 (95% CI 3.3-4.2) and 4.7 months (95% CI 3.9-5.7), respectively.
CONCLUSIONS CONCLUSIONS
Even if a small proportion of patients received a 1L IO, the data showed an improved survival outcomes in the Post-1L IO group.

Identifiants

pubmed: 36139641
pii: cancers14184481
doi: 10.3390/cancers14184481
pmc: PMC9497168
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : MSD (United States)
ID : L1P1652

Références

Cancers (Basel). 2021 Sep 28;13(19):
pubmed: 34638329
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Lung Cancer (Auckl). 2017 Oct 24;8:191-206
pubmed: 29123433
N Engl J Med. 2002 Jan 10;346(2):92-8
pubmed: 11784875
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Crit Rev Oncol Hematol. 2019 Oct;142:26-34
pubmed: 31352168
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Cancer J. 2020 Nov/Dec;26(6):525-536
pubmed: 33298724
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Lung Cancer. 2022 Oct;172:65-74
pubmed: 36007281
Front Oncol. 2021 Mar 05;11:642883
pubmed: 33747966
PLoS One. 2018 Aug 27;13(8):e0202865
pubmed: 30148862
Drugs Aging. 2021 Dec;38(12):1055-1065
pubmed: 34671933
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Clin Lung Cancer. 2018 Sep;19(5):e629-e645
pubmed: 29885945
Lung Cancer. 2017 Oct;112:156-164
pubmed: 29191588
Clin Med Insights Oncol. 2021 Mar 31;15:11795549211004489
pubmed: 34248362
Transl Lung Cancer Res. 2019 Jun;8(3):286-301
pubmed: 31367542
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
Cancer Treat Rev. 2020 Jul;87:102031
pubmed: 32446182
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
PLoS One. 2017 Jun 23;12(6):e0178420
pubmed: 28644837
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856

Auteurs

Valentina Danesi (V)

Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Ilaria Massa (I)

Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Flavia Foca (F)

Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Angelo Delmonte (A)

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Lucio Crinò (L)

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Giuseppe Bronte (G)

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Maria Ragonesi (M)

Nursing Service, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Roberta Maltoni (R)

Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Silvia Manunta (S)

AULSS5, UOC Oncologia, Ospedale Santa Maria della Misericordia, 45100 Rovigo, Italy.

Paola Cravero (P)

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Kalliopi Andrikou (K)

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Ilaria Priano (I)

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

William Balzi (W)

Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Nicola Gentili (N)

Outcome Research, Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.

Thomas Burke (T)

Center for Observational and Real World Evidence, Merck & Co Inc., Kenilworth, NJ 07033, USA.

Mattia Altini (M)

Healthcare Administration, Azienda Unità Sanitaria Locale della Romagna, 48121 Ravenna, Italy.

Classifications MeSH